Suven Pharma Merger with Cohance Lifesciences Secures DoP Clearance

Following the merger, the combined entity will operate under the name Cohance Lifesciences Limited.

Suven Pharmaceuticals has secured the final nod to merge with Cohance Lifesciences.

The contract development and manufacturing organization (CDMO) bagged the final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, for foreign investment under applicable regulations.

This marks the final regulatory clearance necessary to implement the Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals, a transaction that was previously approved by shareholders and sanctioned by the NCLT, Mumbai Bench.

As per the terms outlined in the Scheme of Amalgamation, the merger will come into effect from May 1, 2025, following the fulfillment of all required conditions.

Following the merger, the combined entity will operate under the name Cohance Lifesciences Limited, pending applicable regulatory approvals, and will represent a unified platform with expanded CDMO capabilities.

Vivek Sharma, Executive Chairman, Suven Pharmaceuticals, said, “This approval is a significant milestone and reinforces the strategic vision behind the merger.”

According to Suven Pharmaceuticals, the integration is expected to strengthen the company’s position as an innovation-driven, integrated CDMO partner for global innovators, with a strategic focus on scaling high-growth modalities such as ADCs and oligonucleotides.

Additionally, the Board has approved May 8, 2025, as the Record Date for determining the eligible shareholders of Cohance Lifesciences who will receive equity shares of Suven Pharmaceuticals, by the approved share exchange ratio under the Scheme of Amalgamation.

With the merger now effective, the company has begun operational and organizational integration activities for a smooth transition.

Stay tuned for more such updates on Digital Health News.